Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on June 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved the Restated 2002 Stock Incentive Plan at the June 5, 2026 annual meeting.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved the Restated 2002 Stock Incentive Plan at the June 5, 2026 annual meeting
- Updated plan governs future equity awards and potentially expands compensation flexibility for directors and employees
- Material terms are detailed in the April 21, 2026 proxy statement and Appendix B-priority document for dilution and incentive analysis
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All eight director nominees elected for terms expiring at the 2027 annual meeting
- Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2026
- Executive compensation advisory vote approved, with 16,497,712 votes for
- Amended and restated 2002 Stock Incentive Plan approved, with 16,643,281 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.